Citations 11
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, Al B. , D’Angelica, Michael I., Abbott, Daniel E. , Anaya, Daniel A. , Are, Chandrakanth , Brown, Daniel B. , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon , Karachristos, Andreas , Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Sahai, Vaibhav , Schefter, Tracey E., Singh, Gagandeep , Sohal, Davendra , Stein, Stacey , Tian, Guo , Hammond, Lydia J., Darlow, Susan, Abrams, Thomas A. , Alberts, Steven R. , Anders, Robert A. , Chang, Daniel T. , Hawkins, William G , Sicklick, Jason Keith , Tian, G. Gary, Vauthey, Jean‐Nicolas , Venook, Alan P. , Sahai, Vaibhav
Journal of the National Comprehensive Cancer Network | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 302-310
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.